Physician profile

Michael Sein

Family Medicine · Dawson, GA

NPI 1922070077

$752.24

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$159.37

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $246.80 2019-2023 Trelegy Ellipta
Novo Nordisk INC $165.71 2019-2023 Ozempic, Rybelsus
Medtronic USA, INC. $110.33 2019
Astrazeneca Pharmaceuticals Lp $89.48 2019-2022
Lilly USA, LLC $61.64 2020-2023 Jardiance
Sanofi-Aventis U.S. LLC $32.03 2020-2021
Merck Sharp & Dohme LLC $31.91 2023 Verquvo, Gardasil 9, Vaxneuvance
Janssen Pharmaceuticals, INC $14.34 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Sein

$752.24

in general payments reported 2019-2025

Years
2019-2023
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/1015779/michael-sein

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.